Literature DB >> 32314452

Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study.

A-C Fougerousse1, P-D Ghislain2, Z Reguiai3, F Maccari4, J Parier4, D Bouilly Auvray5, G Chaby6, V Pallure7, J-L Schmutz8, C Clément9, C Jacobzone10, E Begon11, E Esteve12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32314452     DOI： 10.1111/jdv.16511

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

1.  Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period.

Authors:  Yung Chan; Bik Sai Bessie Tong; Pui Yan Ngan; Chi Sum Au
Journal:  Psoriasis (Auckl)       Date:  2021-06-01

2.  Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice.

Authors:  Yi-Teng Hung; Yu-Jr Lin; Hsien-Yi Chiu; Yu-Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2021-09-29       Impact factor: 5.091

Review 3.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

4.  Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.

Authors:  Angelo Ruggiero; Gabriella Fabbrocini; Eleonora Cinelli; Matteo Megna
Journal:  Dermatol Ther       Date:  2021-11-30       Impact factor: 3.858
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.